Equity

Royalty Pharma·Balance Sheet Statement·10 metrics

Breakdown

Loading...

Metrics

Additional paid-in capital

Deferred shares, $0.000001 par value; issued and outstanding: 2026–427,355 and 2025–411,475

Noncontrolling interests

Retained earnings

Share Price

Share Repurchase Authorization Limit

Share Repurchase Program - Amount Remaining

Total liabilities and stockholders' equity

Total stockholders' equity

Treasury stock